Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for AC Immune (ACIU) over the last 12 years, with Q3 2025 value amounting to $15.0 million.

  • AC Immune's Accumulated Expenses rose 69.87% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 69.87%. This contributed to the annual value of $13.8 million for FY2024, which is 9988.95% down from last year.
  • As of Q3 2025, AC Immune's Accumulated Expenses stood at $15.0 million, which was up 69.87% from $13.9 million recorded in Q2 2025.
  • In the past 5 years, AC Immune's Accumulated Expenses registered a high of $18.2 billion during Q4 2021, and its lowest value of $9.4 million during Q1 2023.
  • Its 5-year average for Accumulated Expenses is $3.6 billion, with a median of $13.2 million in 2024.
  • In the last 5 years, AC Immune's Accumulated Expenses soared by 14792333.17% in 2021 and then plummeted by 9994.61% in 2022.
  • AC Immune's Accumulated Expenses (Quarter) stood at $18.2 billion in 2021, then crashed by 99.95% to $9.8 million in 2022, then soared by 127766.13% to $12.5 billion in 2023, then crashed by 99.89% to $13.8 million in 2024, then grew by 8.56% to $15.0 million in 2025.
  • Its Accumulated Expenses stands at $15.0 million for Q3 2025, versus $13.9 million for Q2 2025 and $12.4 million for Q1 2025.